Perion Network Sees Upbeat Q2 Revenue; FDA's FTD Boosts Kazia
- July 06th, 2023
- 333 views
Perion Network Ltd. (Nasdaq: PERI) has released its preliminary results, revealing an anticipated second-quarter 2023 revenue of $176 million, marking a 20% year-over-year increase. This projection surpasses the consensus estimate of $169.88 million for the period.
In pre-market trading, $PERI was observed at $33.18, reflecting a notable rise of $2.30 (7.45%).
In other news, Kazia Therapeutics Limited (Nasdaq: KZIA) has obtained Fast Track Designation (FTD) from the FDA for its drug paxalisib, intended for the treatment of solid tumor brain metastases with PI3K pathway mutations in conjunction with radiation therapy.
FTD aims to accelerate the development of pharmaceutical products addressing unmet medical needs, granting Kazia enhanced access to the FDA, including accelerated approval and priority review possibilities, potentially facilitating faster product approval.
$KZIA was trading at $1.52 in pre-market, up $0.35 (29.91%) following the announcement
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Key Earnings Ahead for Netflix, Fastenal, and U.S. Bancorp
January 18th, 2026Louisville Thunder Appoints Veteran Coach Mike Reed to Lead Program
January 15th, 2026FDA Approves First Treatment for Children With Menkes Disease
January 13th, 2026January 13th, 2026Wall Street Eyes Bank of America, Wells Fargo, Citi Ahead of Earnings
January 11th, 2026
Member Login